Discuss Tesamorelin + Ipamorelin on glp1chat
Join the forum to discuss research with other members.
At a glance
Tesamorelin and ipamorelin both signal the pituitary to release growth hormone, but through different receptors. The combination is studied for the resulting hormone response; results for tesamorelin alone do not establish the combined effect.
Tesamorelin sends a growth-hormone-releasing message to the pituitary, while ipamorelin uses a ghrelin-related receptor. Because both lead toward the same hormone system, a study could measure whether their combined signal changes growth hormone or IGF-1. Tesamorelin's established results in a specific HIV-related fat condition belong to tesamorelin alone. They do not prove the effect of this pair.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Tesamorelin + Ipamorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5mg + 5mg + 10mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Tesamorelin Dose | Ipamorelin Dose | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 125 mcg (0.125 mg) | 23 units (0.23 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 250 mcg (0.25 mg) | 45 units (0.45 mL) |
| Weeks 5–6 | 1000 mcg (1.0 mg) | 500 mcg (0.5 mg) | 90 units (0.90 mL) |
| Weeks 7–10 | 1500 mcg (1.5 mg) | 750 mcg (0.75 mg) | 135 units (1.35 mL) |
| Weeks 11–16 | 2000 mcg (2.0 mg) | 1000 mcg (1.0 mg) | 180 units (1.80 mL) |
Route: Subcutaneous (SC) | Frequency: Once daily Note: The 1:1 blend ratio means tesamorelin and ipamorelin are present in equal amounts per mL. At 3.0 mL reconstitution: 1 mL = 1.67 mg tesamorelin + 1.67 mg ipamorelin. Higher‑volume injections (≥1.0 mL) may be split across two sites if preferred for comfort.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support pulsatile GH release through dual GHRH + ghrelin pathway stimulation[1][2].
- Schedule: Daily subcutaneous injections for 8–16 weeks.
- Dose Range: Tesamorelin 250–2000 mcg + ipamorelin 125–1000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized refrigerated 2–8 °C; reconstituted use immediately or within 24–48 hours.
Suggested daily titration approach.
- Start: 250 mcg tesamorelin + 125 mcg ipamorelin daily; increase every 2 weeks.
- Target: 1500–2000 mcg tesamorelin + 750–1000 mcg ipamorelin by Weeks 7–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–16 weeks.
- Timing: Evening or bedtime administration may align with natural GH secretion patterns[4]; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 24–48 hours[5].
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) up to 3 months after dispensing[5].
- Reconstituted: Inject immediately after reconstitution; if stored, refrigerate and use within 24–48 hours; do not freeze[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][9].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[5][10].
Materials & quantity planning
Source materials checklist · 5mg + 5mg + 10mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 19 vials
- 16 weeks ≈ 31 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (31 vials): 93 mL → 10 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
- 03
Public health resource
NCBI LiverTox — Tesamorelin — Synthetic GHRH analog; recommended dose 2 mg SC daily for HIV lipodystrophy (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PubMed — Ipamorelin, the first selective growth hormone secretagogue — High GH potency and selectivity; no cortisol/ACTH effect (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Public health resource
FDA Egrifta (tesamorelin) Label — SC abdomen injection; rotate sites; storage and reconstitution guidance (opens in a new tab)www.accessdata.fda.gov
Back to overview ↑ - 07
Research publication
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin — Human GH release peaked ~0.67 h post-dose (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
CDC — Vaccine Administration During — General subcutaneous route guidance (angle/site) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best Practices for Injection — Asepsis, preparation, and administration guidance (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
PMC — Subcutaneous Drug Injection Review — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.